Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-10-04 am EDT
1328.40 GBX   +0.67%
02:12aGsk : announces positive headline results from PERLA, the phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer
PU
10/04Vir Biotech gets U.S. funding for flu-prevention antibody
RE
10/04GSK : JP Morgan sticks Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK's Haleon Selects Citigroup, UBS Group of Planned Spinoff on London Bourse

06/27/2022 | 03:14pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CITIGROUP INC. 4.35% 44.41 Delayed Quote.-26.46%
GSK PLC 0.67% 1328.4 Delayed Quote.-19.18%
LONDON STOCK EXCHANGE PLC 1.02% 7718 Delayed Quote.11.37%
UBS GROUP AG 4.39% 15.325 Delayed Quote.-10.60%
All news about GSK PLC
02:12aGsk : announces positive headline results from PERLA, the phase II trial of Jemperli (dost..
PU
10/04Vir Biotech gets U.S. funding for flu-prevention antibody
RE
10/04GSK : JP Morgan sticks Neutral
MD
10/03GSK : Deutsche Bank reiterates its Neutral rating
MD
09/29Haleon Launches Exchange Offers for Seven Series of Notes
MT
09/29Central banks are here to save the day
MS
09/29Ooddo BHF Upgrades GSK to Outperform from Neutral, Lifts PT
MT
09/29Analyst recommendations: Alphabet, Direct Line, Endava, GSK, Vi..
MS
09/29Nestle CEO: I'm not a 'mega deal' maker
RE
09/28Designer Daniel Lee replaces Riccardo Tisci at Burberry
RE
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 28 235 M 32 293 M 32 293 M
Net income 2022 4 477 M 5 120 M 5 120 M
Net Debt 2022 13 727 M 15 700 M 15 700 M
P/E ratio 2022 11,5x
Yield 2022 4,57%
Capitalization 53 778 M 61 509 M 61 509 M
EV / Sales 2022 2,39x
EV / Sales 2023 2,27x
Nbr of Employees 90 096
Free-Float 93,7%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 328,40 GBX
Average target price 1 835,51 GBX
Spread / Average Target 38,2%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-19.18%61 509
JOHNSON & JOHNSON-3.19%429 082
ELI LILLY AND COMPANY16.41%305 529
ROCHE HOLDING AG-15.04%267 122
PFIZER, INC.-24.71%247 729
ABBVIE INC.2.16%244 563